Valuation Charles River Laboratories International, Inc. Berne S.E.
Stocks
RV6
US1598641074
Biotechnology & Medical Research
|
End-of-day quote
Berne S.E.
2026-09-03
|
5-day change | 1st Jan Change | ||
| 233.98 CHF | +0.82% |
|
-3.43% | - |
| Aug. 20 | Charles River Laboratories International Insider Sold Shares Worth $599,711, According to a Recent SEC Filing | MT |
| Aug. 20 | Charles River, Medigen Partner on Multivalent Enterovirus Vaccine | MT |
Company Valuation: Charles River Laboratories International, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 18,941 | 11,138 | 12,252 | 9,520 | 10,023 | 14,004 | - | - |
| Change | - | -41.2% | 10% | -22.3% | 5.29% | 39.72% | - | - |
| Enterprise Value (EV) 1 | 21,366 | 13,616 | 14,622 | 11,565 | 11,946 | 16,116 | 15,635 | 15,241 |
| Change | - | -36.28% | 7.39% | -20.91% | 3.29% | 34.91% | -2.99% | -2.52% |
| P/E | 49.4x | 23.1x | 25.9x | 931x | -70x | 78.5x | 31.4x | 28.1x |
| PBR | 7.45x | 3.75x | 3.41x | 2.75x | 3.17x | 4.65x | 3.95x | 3.51x |
| PEG | - | 0.9x | -9.44x | -9.5x | 0x | -0x | 0x | 2.4x |
| Capitalization / Revenue | 5.35x | 2.8x | 2.97x | 2.35x | 2.5x | 3.58x | 3.5x | 3.33x |
| EV / Revenue | 6.04x | 3.42x | 3.54x | 2.86x | 2.98x | 4.12x | 3.91x | 3.62x |
| EV / EBITDA | 24.3x | 13.7x | 14.4x | 11.6x | 12.3x | 16x | 14.3x | 13x |
| EV / EBIT | 28.8x | 16.3x | 17.4x | 14.3x | 15x | 19.6x | 17.1x | 15.2x |
| EV / FCF | 40.2x | 46.2x | 40x | 23.1x | 23x | 51.1x | 25.7x | 31.9x |
| FCF Yield | 2.49% | 2.17% | 2.5% | 4.34% | 4.34% | 1.96% | 3.9% | 3.13% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 7.6 | 9.48 | 9.22 | 0.2 | -2.91 | 3.738 | 9.346 | 10.43 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 3,540 | 3,976 | 4,129 | 4,050 | 4,015 | 3,911 | 4,001 | 4,208 |
| EBITDA 1 | 879.5 | 990.9 | 1,013 | 996.1 | 971.5 | 1,008 | 1,093 | 1,174 |
| EBIT 1 | 742.1 | 834 | 838.8 | 805.9 | 793.9 | 821 | 912.3 | 1,001 |
| Net income 1 | 391 | 486.2 | 474.6 | 10.3 | -144.3 | 162.4 | 427.7 | 471.2 |
| Net Debt 1 | 2,425 | 2,477 | 2,370 | 2,046 | 1,923 | 2,112 | 1,631 | 1,237 |
| Reference price 2 | 375.34 | 218.92 | 238.84 | 186.16 | 203.66 | 293.35 | 293.35 | 293.35 |
| Nbr of stocks (in thousands) | 50,464 | 50,879 | 51,297 | 51,136 | 49,215 | 47,739 | - | - |
| Announcement Date | 2/16/22 | 2/22/23 | 2/14/24 | 2/19/25 | 2/18/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 33.99x | 6.09x | 18.25x | 0.94% | 50.35B | |
| -21.55x | 255.32x | -23.29x | -.--% | 45.2B | |
| 34.98x | 3.36x | 14.51x | -.--% | 44.71B | |
| 47.51x | 5.49x | 30.13x | -.--% | 41.24B | |
| 28.36x | 8.58x | 21.72x | 0.41% | 33.08B | |
| 33.74x | 5.53x | 25.11x | -.--% | 16.56B | |
| 24.49x | 2.12x | 9.19x | 1.1% | 14.82B | |
| 78.47x | 4.12x | 15.98x | -.--% | 14B | |
| Average | 32.50x | 36.33x | 13.95x | 0.31% | 32.49B | |
| Weighted average by Cap. | 27.77x | 48.81x | 12.51x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CRL Stock
- RV6 Stock
- Valuation Charles River Laboratories International, Inc.
Select your edition
All financial news and data tailored to specific country editions
